רווח למניה בשנים עשר החודשים האחרונים: Candel Therapeutics Inc. (CADL)

The financial stability of Candel Therapeutics (CADL) is based on the prudent allocation of clinical trial budgets and grants. The annual specific profit TTM on GURU.Markets illustrates the yield dynamics, where the current status is -1.50. Candel Therapeutics (CADL) minimizes risks by developing personalized therapy methods for brain and lung cancer. The active phase of clinical trial development confirms the high significance of innovative products in the fight against aggressive tumors.

For Candel Therapeutics (CADL), which is developing sustainable bioethics in cancer immunotherapy, the current trailing twelve-month EPS reflects the efficiency of innovation capitalization under strict cost controls. This indicator is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to assess the real return on a single share of the business and compare profit growth rates with the market price.